Euractiv Est. 1min 21-03-2024 (updated: 08-05-2024 ) Content-Type: Sponsored By Sponsored By An organization or individual has paid to be connected to this work but did not approve or review it. EU’s new Health Technology Assessment Regulation (HTAR) presents a significant opportunity for Europe. [Shutterstock/Aleksandar Karanov] Euractiv is part of the Trust Project >>> Print Email Facebook X LinkedIn WhatsApp Telegram In early 2025, Europe will implement a uniform, pan-EU framework under the new Health Technology Assessment Regulation (HTAR), addressing disparities in evaluating the clinical value of pharmaceuticals and medical devices. The HTAR introduces a Joint Clinical Assessment (JCA) across the continent, a framework mandating that all 27 Member States adopt standardised procedures for evaluating the clinical evidence of newly submitted products or devices. This special report looks at the opportunities, concerns, stakeholders’ readiness and ongoing administrative complexities. Inclusivity, transparency, delivery – navigating the EU’s new Health Technology Assessment Regulation (HTAR) News | Advocacy Lab Content | Health 21-03-2024 Est. 7minThe EFPIA HTA Working Group's Inka Heikkinen and James Ryan spoke with Euractiv’s Nicole Verbeeck, giving insights on moving towards a robust HTA system – one that serves patients, industry and progress in Europe or member states. Under pressure, stakeholders preparing for EU’s new Health Technology Assessment Regulation News | Advocacy Lab Content | Health 21-03-2024 Est. 5minWithin a year, Europe will implement a uniform, pan-EU framework under the new Health Technology Assessment Regulation (HTAR). Concerns remain about stakeholders' readiness and administrative complexities. Realising the potential of HTA Reform Opinion | Promoted content | Health 08-05-2024 Est. 6minThe HTA Regulation was intended to streamline how the value of medicines is assessed, but by overburdening the process, it risks making patients wait for new therapies. Now is the time to come together to ensure we can realise the potential of the EU HTA reform for patients.
